Assembly Biosciences (ASMB) News Today

Assembly Biosciences, Inc. (NASDAQ: ASMB) shares were recently under pressure despite several favorable analyst estimate revisions. The main developments are constructive for the long-term outlook, but they do not include a new clinical, regulatory, or partnership announcement that would provide an immediate catalyst.

• Positive Sentiment: HC Wainwright raised multiple earnings forecasts and maintained its Buy rating. The firm increased its FY2027 estimate from a loss of $0.02 per share to earnings of $0.05, raised its Q2 and Q3 2027 estimates to losses of $0.83 and $0.84 per share, respectively, and lifted its Q4 2027 forecast to $1.67 per share. It also raised its FY2028 estimate to $0.84, FY2030 estimate to $3.32, and FY2029 forecast to a loss of $2.22 per share. HC Wainwright retained a $50 price target, implying substantial upside from recent trading levels.
• Positive Sentiment: The revisions suggest HC Wainwright sees improving future profitability for Assembly Biosciences, particularly beginning in 2027 and extending into 2028-2030. This could support investor confidence in the company’s pipeline and commercial prospects.
• Neutral Sentiment: Management will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference on September 16 at 8:30 a.m. Eastern Time. The presentation could provide updates on Assembly’s viral- and liver-disease programs, but no new information was disclosed in the announcement. Assembly Biosciences conference presentation announcement
• Neutral Sentiment: The reported short-interest data showed zero shares short and a zero-day short-interest ratio, with no meaningful change from the prior period. Because the figures appear anomalous, they provide little insight into current trading pressure.

Overall, the news flow is modestly positive because of improved long-range earnings expectations and the $50 analyst target. However, the absence of a near-term clinical or regulatory catalyst may explain why the stock has not responded more strongly.